期刊
出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.2117402119
关键词
antibodies; chemical biology; biologics; chemically induced dimerization
资金
- National Cancer Institute of the NIH [R43CA240063]
- NIH NCI [CA191018]
- NIH [R35GM122451, GM097316]
- Harry and Dianna Hind Professorship
Monoclonal antibodies with antigen specificity and long serum half-life are crucial in modern therapeutics. We have developed a technology for switchable assembly of functional antibody complexes using chemically induced dimerization domains, allowing control of the antibody's intended function in vivo by modulating the dose of a small molecule.
The antigen specificity and long serum half-life of monoclonal antibodies have made them a critical part of modern therapeutics. These properties have been coopted in a number of synthetic formats, such as antibody-drug conjugates, bispecific antibodies, or Fc-fusion proteins to generate novel biologic drug modalities. Historically, these new therapies have been generated by covalently linking multiple molecular moieties through chemical or genetic methods. This irreversible fusion of different components means that the function of the molecule is static, as determined by the structure. Here, we report the development of a technology for switchable assembly of functional antibody complexes using chemically induced dimerization domains. This approach enables control of the antibody's intended function in vivo by modulating the dose of a small molecule. We demonstrate this switchable assembly across three therapeutically relevant functionalities in vivo, including localization of a radionuclide-conjugated antibody to an antigen-positive tumor, extension of a cytokine's halflife, and activation of bispecific, T cell-engaging antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据